Q3 — Pfizer's Vyndamax (tafamidis)
What did ICER conclude about Vyndamax's value?
A draft report suggested $5,200–$10,400 per year; the final October 2024 report settled on an 85–95% required discount — meaning a fair price of $13,600–$39,000 against a list price approaching $268,000.
The Institute for Clinical and Economic Review, an independent non-profit that assesses drug prices, published a draft report in July 2024 suggesting tafamidis should cost only $5,200 to $10,400 a year, implying a discount of at least 96%. After modelling changes, including how mortality was estimated, the final October 2024 report concluded tafamidis needed a discount of 85% to 95%, equating to $13,600 to $39,000 a year. ICER's findings are not binding, but payers use them in coverage negotiations.